spacer
home > > summer 2019 > overcoming the industry data crisis
PUBLICATIONS


Overcoming the Industry Data Crisis




The amount of data generated around the world is growing exponentially and at rates that are so great they are difficult to grasp. By one calculation, 90% of the world’s data have been generated over the last two years (1). To put it in terms used by the International Data Corporation in its estimates: by 2025, the global datasphere will reach 175 zettabytes − the equivalent of 175 trillion gigabytes (2).

With data from the newest technologies, applications, devices, and wearables all contributing, the sheer breadth of available information in clinical research is staggering, and its potential for contributing positively to modernisation is virtually limitless. The pharmaceutical industry has progressively accepted electronic data capture (EDC) as the standard practice for clinical trials. Overall, the adoption of EDC has resulted in some improvement across the industry − relative to antiquated paper processes − but EDC still largely relies on paper-based source documents (3).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
About the author

 
Ed Seguine, CEO at Clinical Ink, is passionate about creating solutions for problems caused by current clinical trial processes and technologies. With more than 20 years of experience as a clinical technology executive at Big Pharma and startup organisations, Ed, a thought leader on key initiatives including CDISC and eClinical Forum, often presents at industry events and publishes regularly on the benefits of next-generation eSource solutions. He earned a Master of Business Administration from Indiana University, Bloomington, US, and a Bachelor of Science in Finance from Brigham Young University, US.


Print this page
Send to a friend
Privacy statement
News and Press Releases

Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harbouring Exon 20 Insertion Mutations

BEERSE, BELGIUM, May 18, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1 CHRYSALIS study evaluating amivantamab (JNJ-6372) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations.[i] Amivantamab is an EGFR and MET-targeted bispecific antibody, which targets activating and resistance EGFR mutations, and MET pathway activation.[ii],[iii] Investigators assessed efficacy using overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), duration of response, as well as the safety profile of amivantamab,1 which were the basis of the U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation granted earlier this year.[iv]
More info >>

White Papers

PROTEIN:PROTEIN INTERACTION ANALYSIS

IBA GmbH

Groth et al., 2007 and Jasencakova et al., 2010 Protein:protein-interactions (PPI) govern almost all important processes in living organisms. Thus, their rapid and accurate determination and investigation is a major challenge in life sciences. The extremely efficient and fast One-STrEP (Twin-Strep) system is suitable for the isolation of functional protein complexes and subsequent mass spectrometry analysis leads to the identification of protein complex components (Junttila et al., 2005) as it is shown in the following studies.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement